4
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Myocarditis

      chapter-article

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          • Viruses are the most common cause of myocarditis in economically advanced countries.

          • Enteroviruses and adenoviruses are the most common etiologic agents.

          • Viral myocarditis is a triphasic process. Phase 1 is the period of active viral replication in the myocardium during which the symptoms of myocardial damage range from none to cardiogenic shock. If the disease process continues, it enters phase 2, which is characterized by autoimmunity triggered by viral and myocardial proteins. Heart failure often appears for the first time in phase 2. Phase 3, dilated cardiomyopathy, is the end result in some patients. Diagnostic procedures and treatment should be tailored to the phase of disease.

          • Viral myocarditis is a significant cause of dilated cardiomyopathy, as proved by the frequent presence of viral genomic material in the myocardium, and by improvement in ventricular function by immunomodulatory therapy.

          • Myocarditis of any etiology usually presents with heart failure, but the second most common presentation is ventricular arrhythmia. As a result, myocarditis is one of the most common causes of sudden death in young people and others without preexisting structural heart disease.

          • Myocarditis can be definitively diagnosed by endomyocardial biopsy. However, it is clear that existing criteria for the histologic diagnosis need to be refined, and that a variety of molecular markers in the myocardium and the circulation can be used to establish the diagnosis.

          • Treatment of myocarditis has been generally disappointing. Accurate staging of the disease will undoubtedly improve treatment in the future. It is clear that immunosuppression and immunomodulation are effective in some patients, especially during phase 2, but may not be as useful in phases 1 and 3. Since myocarditis is often selflimited, bridging and recovery therapy with circulatory assistance may be effective. Prevention by immunization or receptor blocking strategies is under development.

          • Giant cell myocarditis is an unusually fulminant form of the disease that progresses rapidly to heart failure or sudden death. Rapid onset of disease in young people, especially those with other autoimmune manifestations, accompanied by heart failure or ventricular arrhythmias, suggests giant cell myocarditis.

          • Peripartum cardiomyopathy in economically developed countries is usually the result of myocarditis.

          Related collections

          Most cited references513

          • Record: found
          • Abstract: not found
          • Article: not found

          Neutrophil-activating peptide-1/interleukin 8, a novel cytokine that activates neutrophils.

            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Cardiovascular magnetic resonance assessment of human myocarditis: a comparison to histology and molecular pathology.

            Myocarditis can occasionally lead to sudden death and may progress to dilated cardiomyopathy in up to 10% of patients. Because the initial onset is difficult to recognize clinically and the diagnostic tools available are unsatisfactory, new strategies to diagnose myocarditis are needed. Cardiovascular MR imaging (CMR) was performed in 32 patients who were diagnosed with myocarditis by clinical criteria. To determine whether CMR visualizes areas of active myocarditis, endomyocardial biopsy was taken from the region of contrast enhancement and submitted to histopathologic analysis. Follow-up was performed 3 month later. Contrast enhancement was present in 28 patients (88%) and was usually seen with one or several foci in the myocardium. Foci were most frequently located in the lateral free wall. In the 21 patients in whom biopsy was obtained from the region of contrast enhancement, histopathologic analysis revealed active myocarditis in 19 patients (parvovirus B19, n=12; human herpes virus type 6 [HHV 6], n=5). Conversely, in the remaining 11 patients, in whom biopsy could not be taken from the region of contrast enhancement, active myocarditis was found in one case only (HHV6). At follow-up, the area of contrast enhancement decreased from 9+/-11% to 3+/-4% of left ventricular mass as the left ventricular ejection fraction improved from 47+/-19% to 60+/-10%. Contrast enhancement is a frequent finding in the clinical setting of suspected myocarditis and is associated with active inflammation defined by histopathology. Myocarditis occurs predominantly in the lateral free wall. Contrast CMR is a valuable tool for the evaluation and monitoring of inflammatory heart disease.
              Bookmark
              • Record: found
              • Abstract: not found
              • Article: not found

              MHC-dependent antigen processing and peptide presentation: providing ligands for T lymphocyte activation.

                Bookmark

                Author and article information

                Journal
                978-1-84628-715-2
                10.1007/978-1-84628-715-2
                Cardiovascular Medicine
                Cardiovascular Medicine
                978-1-84628-188-4
                978-1-84628-715-2
                2007
                : 1313-1347
                Affiliations
                [1 ]GRID grid.267308.8, ISNI 0000000092062401, The University of Texas Health Science Center in Houston, ; Houston,
                [2 ]GRID grid.416986.4, ISNI 0000000122966154, Texas Heart Institute, ; Houston, TX USA
                [3 ]GRID grid.5012.6, ISNI 0000000104816099, Department of Cardiology, , University of Maastricht, ; Masstricht, The Netherlands
                [4 ]GRID grid.17635.36, ISNI 0000000419368657, Rasmussen Center for Cardiovascular Disease Prevention Cardiovascular Division, , University of Minnesota, ; Minneapolis, MN USA
                [5 ]GRID grid.66875.3a, ISNI 000000040459167X, Cardiovascular Medicine, , Mayo Clinic College of Medicine, ; Rochester, MN USA
                [6 ]Department of Cardiology, Covance Cardiac Safety Services, Reno, NV USA
                [7 ]Cardiology of Tulsa, Tulsa, OK USA
                [8 ]GRID grid.223827.e, ISNI 0000000121930096, Division of Cardiology, , University of Utah School of Medicine, ; Salt Lake City, UT USA
                Article
                62
                10.1007/978-1-84628-715-2_62
                7123303
                433f9682-25f3-4ecd-87dc-978b48dd20eb
                © Springer-Verlag London Limited 2007

                This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.

                History
                Categories
                Article
                Custom metadata
                © Springer-Verlag London Limited 2007

                kawasaki disease,endomyocardial biopsy,cardiac sarcoidosis,viral myocarditis,scrub typhus

                Comments

                Comment on this article